|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.32 CNY | -0.29% |
|
+0.17% | +0.72% |
| Nov. 02 | Betta Pharmaceuticals Gets Distribution Rights for Hemophilia Drug | MT |
| Oct. 27 | Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 | CI |
| Capitalization | 22.85B 3.22B 2.77B 2.55B 2.45B 4.51B 285B 4.92B 30.4B 11.7B 136B 12.07B 11.83B 498B | P/E ratio 2025 * |
41.8x | P/E ratio 2026 * | 25.8x |
|---|---|---|---|---|---|
| Enterprise value | 24.25B 3.42B 2.94B 2.71B 2.6B 4.79B 303B 5.22B 32.26B 12.42B 145B 12.81B 12.55B 528B | EV / Sales 2025 * |
6.54x | EV / Sales 2026 * | 5.6x |
| Free-Float |
51.51% | Yield 2025 * |
0.66% | Yield 2026 * | 0.85% |
| 1 day | -0.29% | ||
| 1 week | +0.17% | ||
| Current month | -4.52% | ||
| 1 month | -6.89% | ||
| 3 months | -19.96% | ||
| 6 months | +11.06% | ||
| Current year | +0.72% |
| 1 week | 53.01 |  | 55.45 |
| 1 month | 53.01 | | 60.23 |
| Current year | 47.1 | | 79.8 |
| 1 year | 45.71 | | 79.8 |
| 3 years | 30.43 | | 79.8 |
| 5 years | 30.43 | | 143.59 |
| 10 years | 23.19 | | 160.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lie Ming Ding
CEO | Chief Executive Officer | 60 | 2013-08-22 |
Jian Xun Fan
DFI | Director of Finance/CFO | 54 | 2017-03-30 |
Mao Li
CTO | Chief Tech/Sci/R&D Officer | 68 | 2025-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yan Ki Wong
BRD | Director/Board Member | 53 | 2020-12-31 |
Lie Ming Ding
CHM | Chairman | 60 | 2013-08-22 |
Wei Wang
BRD | Director/Board Member | 58 | 2019-11-21 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.36% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.29% | +0.17% | +11.98% | +7.82% | 3.22B | |
| -3.21% | +7.40% | -19.73% | -35.80% | 59.37B | |
| -0.24% | +2.91% | -3.00% | -21.14% | 8.44B | |
| -1.63% | +2.62% | +29.78% | +29.90% | 8.24B | |
| -0.08% | +10.60% | +23.96% | +80.96% | 6.91B | |
| +3.14% | +8.41% | +2.12% | +137.61% | 6.44B | |
| +2.21% | -2.71% | +200.39% | +55.23% | 3.81B | |
| -1.57% | -1.66% | +14.12% | +67.41% | 2.56B | |
| +1.26% | -2.22% | +24.38% | +30.43% | 2.58B | |
| +0.19% | +2.29% | -13.95% | +11.65% | 2.03B | |
| Average | -0.02% | +2.67% | +27.01% | +36.41% | 10.36B | |
| Weighted average by Cap. | -1.73% | +5.64% | +0.96% | -0.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.71B 523M 450M 415M 397M 733M 46.35B 798M 4.94B 1.9B 22.13B 1.96B 1.92B 80.79B | 4.31B 607M 523M 482M 462M 852M 53.86B 927M 5.74B 2.21B 25.71B 2.28B 2.23B 93.88B |
| Net income | 545M 76.74M 66.05M 60.87M 58.31M 108M 6.8B 117M 725M 279M 3.25B 288M 282M 11.86B | 871M 123M 106M 97.35M 93.25M 172M 10.88B 187M 1.16B 446M 5.19B 460M 451M 18.97B |
| Net Debt | 1.4B 197M 170M 156M 150M 276M 17.48B 301M 1.86B 716M 8.34B 739M 724M 30.46B | 1.28B 181M 156M 143M 137M 253M 16.03B 276M 1.71B 657M 7.65B 678M 664M 27.94B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-11-14 | 54.32 ¥ | -0.29% | 5,549,094 |
| 25-11-13 | 54.48 ¥ | +1.06% | 5,086,301 |
| 25-11-12 | 53.91 ¥ | -0.15% | 5,282,787 |
| 25-11-11 | 53.99 ¥ | +0.07% | 3,706,456 |
| 25-11-10 | 53.95 ¥ | -0.52% | 7,648,249 |
End-of-day quote Shenzhen S.E., November 13, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300558 Stock
Select your edition
All financial news and data tailored to specific country editions
